Traders should monitor enrollment completion in mid-2026 and eGFR slope data in Q2 2027 as key catalysts. While reduced losses and strong cash position de-risk near-term execution, absence of revenue and continued net losses limit bullishness. Positive clinical momentum supports long-term upside, but stock remains binary on Phase 3 outcomes.
PROK drugs
PROK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 19 $1.95entry
- T+1 · 8mo ago −1.03%α +0.72% · $1.93
- T+5 · 8mo ago −9.23%α −7.02% · $1.77
- T+20 · 7mo ago +11.79%α +4.17% · $2.18
- T+60 · 5mo ago −14.36%α −28.70% · $1.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ProKidney reported financial results for 2025, highlighting a reduction in net loss to $151.6 million from $163.3 million in 2024, driven by lower R&D and G&A expenses. The company maintains a strong clinical trajectory with FDA alignment on an accelerated approval pathway for rilparencel based on eGFR slope, and completed enrollment in its Phase 3 PROACT 1 trial is expected by mid-2026, with pivotal data readout anticipated in Q2 2027. Cash reserves totaled $270.0 million at year-end, sufficient to fund operations into mid-2027.
Key Financial Metrics
Key Facts
- Net loss before noncontrolling interest decreased to $151.6 million in 2025 from $163.3 million in 2024.
- R&D expenses declined to $114.1 million (from $127.7M) due to completion of prior trials, partially offset by increased costs in the ongoing PROACT 1 study.
- G&A expenses fell to $51.8 million (from $56.1M), driven by lower impairment and equity compensation charges.
- Cash, cash equivalents, and marketable securities totaled $270.0 million as of December 31, 2025, down from $358.3 million in 2024.
- Company reaffirmed cash runway into mid-2027, aligning with Phase 3 trial milestones.
- FDA confirmed eGFR slope as a valid surrogate endpoint for accelerated approval of rilparencel in a July 2025 Type B meeting.
- Phase 3 PROACT 1 enrollment on track for completion in mid-2026, with topline data expected Q2 2027.
Financial Impact
Reduced annual cash burn by ~$11.7 million year-over-year; ending cash balance of $270.0 million supports operations into mid-2027.
Risk Factors
- Clinical trial results may not meet expectations, particularly the eGFR slope endpoint in 2027.
- Regulatory risk: FDA may require additional data beyond the accelerated pathway despite current alignment.
- Cash runway estimate assumes no delays or cost overruns; any setback could necessitate earlier dilutive financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258574 |
Track record
13 reports on PROK
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
- May 15, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers